The Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Aarti Pharmalabs to clarify discrepancies found in the financial results it filed in XBRL format for the quarter ended 30 June 2025, under SEBI Listing Regulations. The company has not yet submitted its response to the exchange. XBRL is the standard digital format companies use to file financial results. The issue appears to be a technical or reporting discrepancy rather than a financial misstatement at this stage.
This is currently a routine compliance query and is not a penalty or enforcement action. Investors should watch for the company's response, as unresolved discrepancies could lead to further exchange action or mild negative sentiment, but no immediate material impact is expected.